Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

The study stated early recognition and aggressive treatment of childhood-onset MMP are essential to prevent permanent scarring.

Multicenter Study Sheds Light on Pediatric MMP

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Researcher Jiyeon Oh shares results of a recent study that confirm the prevalence of AD is stable, but disease burden is rising.

Atopic Dermatitis Insights on Global Prevalence, Health Care Implications, and the Impact of COVID-19

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: April 2, 2025

Hand eczema affects 22.4% of adults in East Greenland, with prevalence, severity, and risk factors mirroring trends other populations.

Hand Eczema Prevalence and Patterns in East Greenland Similar to Nordic and European Trends

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

is Professor and Chair Emeritus of the Department of Dermatology at the University of California, Irvine, where he heads one of the world’s premier laser and skin surgery facilities.

Christopher B. Zachary, MBBS, MRCP, FRCP, shares insights in apoptosis-based skin care treatment.

Apoptosis-Based Skin Cancer Treatment Shows Promise

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

Melinda Gooderham, MD, MSc, FRCPC: Reaffirming Delgocitinib Safety With Minimal Absorption, Maximum Confidence

2025 American Academy of Dermatology Annual Meeting

 in Orlando, Florida, Melinda Gooderham, MD, MSc, FRCPC, a dermatologist and clinical researcher from Peterborough, Ontario, Canada, provided further insights into the safety and systemic exposure profile of delgocitinib cream (LEO Pharma) for chronic hand eczema (CHE).

, Gooderham emphasized the importance of safety data, global regulatory approval considerations, and the potential for expanded indications and future comparative studies. Readers can view part 1 of this discussion 

Gooderham reiterated that delgocitinib’s systemic absorption remained minimal even under maximal use conditions. This conclusion builds upon previous research that assessed systemic exposure in both the CHE patient population and a phase 1 trial evaluating delgocitinib in moderate to severe atopic dermatitis.

"Because we had previously reported on the minimal absorption in the past in the whole cohort, looking at those with the maximal use, there was nothing unexpected," Gooderham explained. "It kind of confirmed what we thought—that even patients using a higher amount of product or covering more body surface area in the phase 1 trial for atopic dermatitis—it wasn't surprising; it was more reassuring."

The findings reinforce the safety profile of topical delgocitinib and provide reassurance to both prescribers and patients. Notably, even in cases where patients use the product on larger areas, there was no indication of concerning systemic absorption.

As delgocitinib has already gained approval in some regions, Gooderham noted that additional regulatory submissions and approvals worldwide will benefit from this safety data. 

"Moving forward, delgo[citinib] is already approved in a couple of regions, but there will be regulatory submissions and approvals more globally, and having this safety data will help with those approvals," she said.

Furthermore, these findings could influence product labeling by offering more comprehensive safety information to prescribing physicians. 

"Maybe it will also impact the label that is put on these products," Gooderham added, highlighting the potential for expanded indications or more detailed guidance on usage.

While delgocitinib’s safety and efficacy profile is promising, Gooderham underscored the importance of future comparative studies. 

"As far as the development, hopefully we could have in the future some head-to-head studies," she said, "so we can look more at how it's working compared to a topical steroid or a topical calcineurin inhibitor or PDE4 inhibitor. Head-to-head studies are always great for informing prescribers and patients when they're making choices."

Additionally, Gooderham emphasized the necessity of real-world data to assess delgocitinib’s long-term effectiveness and safety in clinical practice. 

"I think we'll also need to have some real-world studies come out on how delgocitinib is working in the real world as far as efficacy and safety, of course," she noted. "That’s what we're trying to show in this poster—that there's less concern of safety issues when you're using a JAK inhibitor topically."

Despite delgocitinib’s current approvals for CHE, Gooderham acknowledged that clinicians might prescribe it for other types of eczema. 

"One thing that I didn’t mention earlier is that although delgocitinib is approved for chronic hand eczema, we know that patients may use it on other areas of eczema, or prescribers might be using this product off-label," she said.

This is particularly relevant given the reassuring findings on systemic absorption. "Having this data, knowing that the absorption is negligible, even under maximal use conditions, I think moving forward, will open up options for patients and potential future indications," she added.

LEO Pharma presents new late-breaking delgocitinib cream data for the third consecutive year at AAD 2025. News release. Business wire. March 8, 2025. Accessed March 31, 2025. 

https://www.businesswire.com/news/home/20250308530521/en/LEO-Pharma-Presents-New-Late-Breaking-Delgocitinib-Cream-Data-For-the-Third-Consecutive-Year-at-AAD-2025

Gooderham M, Eichenfield LF, Bunick CG, et al. Delgocitinib cream has negligible systemic exposure in patients with maximal use of delgocitinib cream for the treatment of chronic hand eczema. Presented at: American Academy of Dermatology (AAD) Annual Meeting; March 2025; Orlando, FL.

At the 2025 AAD Annual Meeting, Gooderham shared data on the negligible systemic exposure of delgocitinib cream for chronic hand eczema.

Melinda Gooderham, MD, MSc, FACPC: Minimal Systemic Exposure of Delgocitinib Cream in Chronic Hand Eczema

 in Orlando, Florida, Melinda Gooderham, MD, MSc, FRCPC, a dermatologist and clinical researcher from Peterborough, Ontario, Canada, presented findings on the systemic exposure of delgocitinib cream (LEO Pharma) under maximal use conditions in chronic hand eczema (CHE).

The study, presented in a poster titled, "Delgocitinib cream has negligible systemic exposure in patients with maximal use of delgocitinib cream for the treatment of chronic hand eczema," was aimed at evaluating the systemic exposure of twice-daily delgocitinib cream in patients with CHE using it at the upper quartile of usage during the phase 3 DELTA 2 trial.

In addition, the study compared the systemic exposure of delgocitinib cream with data from phase 1 trials, which investigated the use of delgocitinib in moderate to severe atopic dermatitis. The goal was to analyze systemic absorption differences between topical application on a larger body surface area and oral administration.

 spoke with Gooderham to discuss highlights and takeaways from the research.

"We have previously presented on the systemic exposure, but the purpose of this poster at the AAD was to look at the systemic exposure of twice daily delgocitinib cream under maximal use conditions," Gooderham said. "And then we wanted to compare that systemic exposure with data from the phase 1 trials which looked at delgocitinib cream used for moderate to severe atopic dermatitis, so on a wider body surface area, as well as looking at an oral dose that was given in a phase 1 trial, just to compare the systemic absorption of topical use on a larger body surface area, also one that was provided orally."

The study demonstrated minimal systemic absorption of delgocitinib cream, with the highest observed peak systemic exposure recorded at 7.2 ng/mL. In comparison, an oral dose of delgocitinib (1.5 mg) administered in a phase 1 trial resulted in a much higher mean exposure of 99.3 ng/mL. 

Gooderham highlighted the clinical significance of these findings: "I think the most important clinical implication is the lack of side effects. We know that JAK inhibitors have been given a black box warning, which makes both prescribers concerned; it makes patients concerned. It showed that there's negligible systemic exposure, which provides a lower risk of systemic side effects. It gives it a more favorable safety profile, and patients will be more comfortable using this on a longer term basis."

The safety profile of delgocitinib cream was favorable, with adverse events reported in 45.7% of patients in the delgocitinib group, and 44.7% in the vehicle group. The most common adverse event was COVID-19 infection, with only one serious adverse event (1.1%) in the delgocitinib group, which was unrelated to the treatment. Importantly, there were no reports of malignancy, major cardiovascular events, or venous thromboembolic events.

Gooderham noted, "We don't have a lot of maximum exposure done with topical steroids that we're commonly using on large body surface areas for our patients. It's nice to be able to reassure patients that these studies have been done when they're putting these creams on for chronic hand eczema."

Gooderham also placed delgocitinib in the broader context of topical treatments, comparing it to other options such as topical corticosteroids and topical calcineurin inhibitors. She added, "We know there's other systemic side effects or local side effects with the use of topical corticosteroids. There are issues with using topical calcineurin inhibitors, but recent data looking at topical JAK inhibitors, we have another with topical ruxolitinib, which also showed limited systemic absorption with topical use. So I think this is adding to that safety profile with these medications so that they can be used with comfort and prescribed by prescribers with comfort."

Melinda Gooderham, MD, MSc, FRCPC: Minimal Systemic Exposure of Delgocitinib Cream in Chronic Hand Eczema

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

Each year, dermatology clinicians have a plethora of conferences to attend across the US, and even internationally. Although you may not be able to attend them all, there is no shortage of new data presented at each conference. Specific meetings geared towards dermatology advanced practice providers are growing in both quantity and size. Just last month, the inaugural Inflammatory Disease Summit in Las Vegas, Nevada, kicked off an exciting first year. 

Out of the meetings listed below, which one did you enjoy the most? Or, email us at 

As we get ready to plan for a busy 2024, check back for additional meeting opportunities!

Fall Clinical Dermatology Conference for PAs & NPs

Society of Dermatology Nurse Practitioners

Society of Dermatology Physician Assistants

Dermatology Education Foundation (DEF) - DERM2023 NP/PA CME Conference 

DEF Biologic & Small Molecule NP/PA CME Bootcamp

Masterclasses in Psoriatic Disease Plus for APP+

Dermatology clinicians have numerous conferences to choose from annually, both domestically and internationally, offering abundant new data. The number of meetings specifically for dermatology advanced practice providers is increasing in both frequency and scale. Recently, the inaugural Inflammatory Disease Summit in Las Vegas marked an exciting new addition to the dermatology conference landscape. As the planning for 2024 begins, more meeting opportunities are anticipated, providing further chances for professionals to engage with the latest advancements and share their experiences within the field.

Click here to answer this week's NP & PA poll. Out of the meetings listed below, which one did you enjoy the most?

POLL: Which of the Following 2023 NP & PA Conferences Has Been Your Favorite?

Lisa M. Arkin, MD, associate professor and director of pediatric dermatology at the University of Wisconsin, Madison, emphasized the importance of collaboration between pediatric dermatologists and laser surgeons in treating vascular anomalies at the 

she said that bringing together specialists with different perspectives is essential for developing more precise, effective treatments for young patients.

Optimizing Laser Therapy for Vascular Anomalies: Why Early, Multidisciplinary Care Matters

Arkin highlighted that vascular anomalies require a multidisciplinary approach, as no single treatment modality works for all cases. Although laser therapy generally works well for port wine birthmarks, she told 

that other vascular anomalies often require a combination of treatments, including systemic therapies like propranolol for infantile hemangiomas. She stressed the importance of building a network of colleagues across specialties to ensure the best patient outcomes.

“The first step is really to build your village,” she told 

. “You want a village of other folks who can help with systemic therapy or procedural interventions, propranolol for infantile hemangiomas. And then you want to get a community of laser surgeons who can help you if you're new to treating with laser, because there are a lot of pitfalls that can happen in these.”

One of the key points Arkin discussed was the importance of early intervention.

 that there is strong evidence supporting the benefits of treating port wine birthmarks early, as laser therapy is most effective when the skin is thinner and has less melanin, allowing better light penetration. She encouraged dermatologists to refer patients as soon as possible to maximize treatment success.

For infantile hemangiomas, Arkin advised that laser treatment should not be overlooked once the lesions are stabilized on systemic therapy. However, she cautioned that clinicians must be vigilant for warning signs such as early ischemia, which can indicate ulceration risk. Thoughtful and strategic treatment planning is essential to avoid complications, Arkin added.

When treating complex vascular anomalies, Arkin explained that selecting the appropriate laser wavelength is critical. Factors such as lesion depth, dominant chromophore, and energy levels must be carefully balanced to achieve optimal results, she told 

. She stressed that laser therapy should be integrated into a broader treatment strategy rather than viewed as a standalone solution.

Ultimately, Arkin underscored that pediatric dermatologists and laser surgeons working together can significantly improve patient outcomes. “I think pediatric dermatologists and laser surgeons working together will improve outcomes for our patients,” she told 

. “And in some ways, we want to see the world from different perspectives. So being able to negotiate and navigate and listen to other perspectives, it's going to bring the field forward… Collaboration is key.”

1. Arkin LM. Critical Gaps and Controversies in Laser Treatment of Port Wine Birthmarks and other Vascular Anomalies. Presented at the 2025 AAD Annual Meeting; March 7-11; Orlando, Florida.

2.Geronemus RG, Duerr HA. Early Intervention for Port-Wine Stains. 

https://www.dermatologytimes.com/view/early-intervention-for-port-wine-stains

Lisa M. Arkin, MD, shared how early laser treatment and multidisciplinary approaches improves outcomes for vascular anomalies. 

Christopher B. Zachary, MBBS, MRCP, FRCP

Articles

Latest Updated Articles